Clinical Trial Update: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A first-in-human master protocol evaluating next-generation engineered T cells targeting NY-ESO-1 and/or LAGE-1a in advanced solid tumors has been terminated, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Adaptimmune NY-ESO-1/LAGE-1a TCR-engineered T cells

Snippet

Sponsor: Adaptimmune | Conditions: Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2024-05-10